Mitsubishi Tanabe Pharma Corporation
$92.7K 45 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Banner Life Sciences, LLC
Banner Life Sciences, LLC reported $92,759.11 across General Payments, Research, and Ownership to 2,044 physicians and teaching hospitals across 2,050 transactions.
- $92.8K Below-median payer
- All-tracks total
- 2,050 Top quartile volume
- Transactions
- 2,044 Top quartile reach
- Recipients
- −$24.5K
- General Payments vs PY2023
Banner Life Sciences, LLC reported $92,759.11 across all CMS Open Payments tracks (General + Research + Ownership) to 2,044 physicians and teaching hospitals in Program Year 2024 - ranking #1202 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $82,357.51, averaging $45.38 per recipient.
How Banner Life Sciences, LLC's $92.8K all-tracks total breaks down
Banner Life Sciences, LLC's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
25/100
Total payments
F
11/100
Transaction volume
F
25/100
Physician reach
F
25/100
Payment type diversity
F
37/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer banner-life-sciences-llc Banner Life Sciences, LLC
$92.8K · #1202/1,925 · 0.0% industry · PY2024
- TOT $92.8K
- RANK #1202
- SHARE 0.0%
- TXN 2,050
- RCP 2,044
- CAT 3
- GEN $82.4K
- ΔGEN −$24.5K
- TOP1 16.9%
- PY 2024
Volume peers
Nearest volume peer: Mitsubishi Tanabe Pharma Corporation ($92.7K)
Banner Life Sciences, LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Banner Life Sciences, LLC's CMS-reported General Payments decreased by $24.5K (−22.9%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: BANNER LIFE SCIENCES, LLCPY2023: BANNER LIFE SCIENCES, LLCPY2024: BANNER LIFE SCIENCES, LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $106,829.32
- PY2024
- $82,357.51
What the Data Shows for Banner Life Sciences, LLC
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Banner Life Sciences, LLC, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
2,027 transactions worth $42.7K make "Food and Beverage" the top general-payment category in the 3-category breakdown below, 51.8% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Food and Beverage" leads Banner Life Sciences, LLC's 3-category general-payment breakdown at $42.7K, 51.8% of the reported total.
How Banner Life Sciences, LLC divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $42.7K | 2,027 | 51.8% |
| Compensation for Services Other Than Consulting | $34.7K | 16 | 42.1% |
| Space Rental or Facility Fees | $5.0K | 1 | 6.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $35,738.69 (43.4%) of $82,357.51 in this company's General Payments records across 827 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Banner Life Sciences, LLC
The five named recipients with the highest reported General Payments from this company
- 1
Rebecca Jones
$13,938.79 across 35 reported transactions
- 2
Ajo Joy
$7,106.94 across 6 reported transactions
- 3
Sangjin Oh
$5,012.55 across 25 reported transactions
- 4
Vanderbilt University Medical Center
$5,000.00 across 1 reported transactions
- 5
Mary Ann Picone
$4,680.41 across 5 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Banner Life Sciences, LLC's spend rank (#1202 of 1,925, bottom 38% by spend) and concentration rank (#1,297 of 1,838, bottom 29% least concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Merge Healthcare Incorporated : $6.9K total payments, HHI 499
- Alnylam Pharmaceuticals Inc. : $6.5M total payments, HHI 498
- Nxstage Medical, Inc. : $106.2K total payments, HHI 496
- Adaptive Biotechnologies Corporation : $462.3K total payments, HHI 495
- Iovance Biotherapeutics, Inc. : $114.7K total payments, HHI 489
- Arjo Inc. : $151.8K total payments, HHI 489
- Banner Life Sciences, LLC (this company) : $82.4K total payments, HHI 487
- FUJIFILM Sonosite, Inc. : $257.0K total payments, HHI 486
- restor3d, inc. : $1.6M total payments, HHI 486
- Micro-tech Endoscopy USA, Inc. : $159.3K total payments, HHI 483
- International Life Sciences : $883.8K total payments, HHI 481
- Octapharma USA, Inc. : $1.0M total payments, HHI 480
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Banner Life Sciences, LLC's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Banner Life Sciences, LLC.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Banner Life Sciences, LLC.
Showing 6 of 1,924 companies with CMS-reported payment data.
Mid-Atlantic Surgical Systems, LLC
$92.4K 919 recipients
Compare payment profiles
Cardinal Health 110 LLC
$92.3K 166 recipients
Compare payment profiles
Okami Medical, Inc.
$92.0K 263 recipients
Compare payment profiles
OnMark, Inc.
$93.7K 63 recipients
Compare payment profiles
AGEPHA Pharma FZ LLC
$93.7K 510 recipients
Compare payment profiles
Put this to use
Banner Life Sciences, LLC ranks #1202 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Banner Life Sciences, LLC. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.